Tag: KB003

Posted on

KaloBios to Stop KB003 Development for Asthma – Analyst Blog – NASDAQ

KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ
KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant …
KaloBios shares tank on failed asthma drug trialSan Francisco Business Times (blog)
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
MarketWatch
all 32 news articles »

View full post on asthma – Google News

Posted on

KaloBios to Stop KB003 Development for Asthma – Zacks.com

KaloBios to Stop KB003 Development for Asthma
Zacks.com
KaloBios Pharmaceuticals, Inc. (KBIO – Snapshot Report) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a …
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
KaloBios Shares Slide on Move to Stop Asthma Treatment StudyWall Street Journal
RTT News –San Francisco Business Times (blog)
all 30 news articles »

View full post on asthma – Google News

Posted on

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal … – The Herald | HeraldOnline.com

KaloBios Initiates Phase 2 Study with KB003 Humaneered™ Monoclonal …
The Herald | HeraldOnline.com
KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered™ monoclonal antibody, in subjects with severe asthma …

and more »

View full post on asthma – Google News